Drug news
Settlement of AbbVIe and Amgen litigation concerning Amgevita/Amjevita (adalimumab biosimilar).- Amgen
Amgen has announced that it has reached a global settlement with AbbVie to resolve all pending litigation regarding Amgevita/ Amjevita, a biosimilar to AbbVie's Humira (adalimumab). Under terms of the agreement, AbbVie will grant patent licenses for the use and sale of Amgevita/Amjevita worldwide, on a country-by-country basis, and the companies have agreed to dismiss all pending litigation.
Amgen expects to launch Amgevita in Europe on 6 October 2018 , and Amjevita in the United Stateson 31 January 2023.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.